Quantumzyme to Attend 2026 BIO International Convention for Industry Engagement

Quantumzyme Corp., a biotransformation company focused on enzyme-based solutions for pharmaceutical manufacturing, announced plans to attend the 2026 BIO International Convention scheduled for June 22–25, 2026, in San Diego, California. The convention represents a global gathering of biotechnology and life sciences companies, academic institutions, and industry participants across scientific and commercial disciplines. This attendance matters because it demonstrates Quantumzyme's strategic approach to industry engagement during a period of significant technological evolution in biomanufacturing.

Company representatives will attend the conference to engage in informal networking meetings with industry participants, though Quantumzyme will not be presenting, exhibiting, sponsoring, or formally participating in conference programming. According to Naveen Kulkarni, Chief Executive Officer of Quantumzyme Corp., the convention provides an important opportunity to connect with peers across the biotechnology and biomanufacturing ecosystem. The company's attendance is focused on listening, learning, and engaging in informal discussions with industry participants as it continues to evaluate developments relevant to its technology and long-term objectives.

This limited attendance approach, consisting of observation and networking activities only, aligns with Quantumzyme's ongoing efforts to increase industry awareness and maintain dialogue with potential collaborators, technology partners, and other stakeholders. The importance of this engagement lies in the company's specialized focus on applying quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to develop biocatalysts designed to enhance efficiency, reduce waste, and support environmentally responsible pharmaceutical production. However, the company noted there can be no assurance that discussions initiated during the conference will result in any agreements, transactions, or future business relationships.

The announcement highlights Quantumzyme's positioning within the broader biotechnology landscape as companies increasingly seek sustainable manufacturing solutions. The company's computational approach to enzyme engineering represents a growing trend toward integrating advanced modeling with laboratory validation to deliver scalable, cost-effective biocatalysis solutions. Additional information regarding the BIO International Convention is available at https://convention.bio.org. For more information and updates, please visit https://www.quantumzymecorp.com and the company's profile at https://www.otcmarkets.com/stock/QTZM.